TMS-ENTERTAINMENT-PARIS
1.2.2021 08:32:12 CET | Business Wire | Press release
TMS Entertainment today announced that MEGALOBOX 2: NOMAD , the highly anticipated sequel to the internationally acclaimed anime series MEGALOBOX , will premiere in April 2021 on Japanese television networks TOKYO MX and BS11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210131005078/en/
MEGALOBOX , a series based on Tomorrow’s Joe by Asao Takamori (Ikki Kajiwara) and Tetsuya Chiba, was originally released in 2018 to commemorate the 50th anniversary of the original manga title.
Teaser Trailer and Visuals Revealed
The teaser trailer and visuals have also been revealed ahead of the broadcast.
Watch the teaser now: https://youtu.be/bjl0qMgrugQ
The striking teaser visual, drawn by the director Yo Moriyama, shows Joe standing with his gear covering the body full of scars. Seven years after Joe’s reign as the first Megalonia champion, we now find him calling himself Nomad. The accompanying teaser trailer reveals a glimpse of what had happened to Joe after the fateful match with Yuri in MEGALOBOX.
ABOUT MEGALOBOX 2: NOMAD
In the end, “Gearless” Joe was the one that reigned as the champion of Megalonia, a first ever megalobox tournament. Fans everywhere were mesmerized by the meteoric rise of Joe who sprung out from the deepest underground ring to the top in mere three months and without the use of gear. Seven years later, “Gearless” Joe was once again fighting in underground matches. Adorned with scars and once again donning his gear, but now known only as Nomad…
WEB
: https://megalobox.com/
Twitter
: https://twitter.com/joe50_megalobox
STAFF
Original Concept: Tomorrow’s Joe
Original Comic Books Created by Asao Takamori, Tetsuya Chiba / Published by Kodansha.
Director / Concept Designer: Yo Moriyama
Scenario: Katsuhiko Manabe, Kensaku Kojima
Character Designer: Ayumi Kurashima
Sub Character Designer: Naomi Kaneda
Music: mabanua
Animation production: TMS Entertainment Co., Ltd.
Produced by MEGALOBOX2 Project
CAST
Joe / NOMAD: Yoshimasa Hosoya
GANSAKU NANBU: Shiro Saito
YURI: Hiroki Yasumoto
SACHIO: Michiyo Murase
© Asao Takamori, Tetsuya Chiba/Kodansha/MEGALOBOX2 project. All Rights Reserved.
About TMS Entertainment
By maintaining a balance of creativity and business production, TMS Entertainment provides a one-stop shop for services from IP creation to consumer satisfaction improvement, centered around its animation production, licensing, and content businesses. TMS Entertainment has continuously produced much-loved anime titles in Japan, including "Lupin the 3rd," "Dr. STONE," and “MEGALOBOX” while connecting its library of over 12,000 episodes across a total of 420 titles to its global business.
WEB
: https://www.tms-e.co.jp/global/
Twitter:
https://twitter.com/tmsanime
Facebook:
https://www.facebook.com/AnimeTMS
Instagram:
https://www.instagram.com/tmsanime/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210131005078/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom